<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="210">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02255279</url>
  </required_header>
  <id_info>
    <org_study_id>V70_50</org_study_id>
    <nct_id>NCT02255279</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to &lt;72 Months of Age in Mexico.</brief_title>
  <official_title>A Phase 3, Observed-Blind, Randomized, Multi-center Study to Evaluate Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to &lt;72 Months of Age in Mexico.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>COFEPRIS:Comision federal para la Proteccion contra Riesgos Sanitarios</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The administration of adjuvanted Trivalent Influenza Vaccine (aTIV) has come to result in a
      more immunogenic and effective response compared with conventional influenza vaccines in
      elderly and adults.

      The aim of this study is to evaluate safety and immunogenicity of Novartis aTIV in children
      6 to &lt;72 months of age, Mexican population, in comparison to Fluzone, a non-adjuvanted
      trivalent influenza vaccine (TIV).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Naive Subjects 6 to &lt; 36 Months Old Reporting Solicited Local and Systemic Adverse Events (AEs) From Day 1 to Day 7 Following Each Vaccination.</measure>
    <time_frame>From Day 1 to Day 7 by vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of naive subjects 6 to &lt; 36 months old reporting solicited local and systemic AEs from Day 1 to Day 7 after first vaccination and from Day 29 to Day 35 after second vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Non-naive Subjects 6 to &lt; 36 Months Old Reporting Solicited Local and Systemic AEs From Day 1 to Day 7 After Vaccination.</measure>
    <time_frame>From Day 1 to Day 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of non-naive subjects 6 to &lt; 36 months old reporting solicited local and systemic AEs from Day 1 to Day 7 after vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Naive Subjects ≥ 36 Months to &lt; 72 Months Old Reporting Solicited Local and Systemic AEs From Day 1 to Day 7 Following Each Vaccination.</measure>
    <time_frame>From Day 1 to Day 7 by vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of naive subjects ≥ 36 months to &lt; 72 months old reporting solicited local and systemic AEs from Day 1 to Day 7 after first vaccination and from Day 29 to Day 35 after second vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Non-naive Subjects ≥36 Months to &lt; 72 Months Old Reporting Solicited Local and Systemic AEs From Day 1 to Day 7 Following Each Vaccination.</measure>
    <time_frame>From Day 1 to Day 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of non-naive subjects ≥36 months to &lt; 72 months old reporting solicited local and systemic AEs from Day 1 to Day 7 after vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Naive Subjects Aged 6 to &lt; 72 Months Reporting All Unsolicited AEs From Day 1 to Day 50.</measure>
    <time_frame>From Day 1 to Day 50</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of naive subjects aged 6 to &lt; 72 months reporting all unsolicited AEs, medically attended AEs, AE leading to study withdrawal and serious AEs (SAEs) from Day 1 to Day 50.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Non-naive Subjects Aged 6 to &lt; 72 Months Reporting All Unsolicited AEs From Day 1 to Day 22</measure>
    <time_frame>From Day 1 to Day 22</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of non-naive subjects aged 6 to &lt; 72 months reporting all unsolicited AEs, medically attended AEs, AE leading to study withdrawal and SAEs from Day 1 to Day 22.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs), in All Three Homologous Virus Strains in Subjects 6 to &lt; 72 Months of Age.</measure>
    <time_frame>Day 1 and Day 22 (vaccine non-naïve subjects) or Day 50 (vaccine naïve subjects) post vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Antibody response was assessed in terms of GMTs in all three homologous virus strains, 21 days after last immunization, in subjects 6 to &lt;72 months of age.
The study is considered a success if the 21 days after last immunization GMT ratios of aTIV relative to TIV demonstrate as non-inferior with the lower limit (LL) of the two sided 95% confidence interval (CI) above 0.67 (-0.176 on log10 scale) for each vaccine strain (Center for Biologics Evaluation and Research {CBER} Guideline on Seasonal Vaccines May 2007).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects Achieving Seroconversion in Hemagglutination Inhibition (HI) Titers and Vaccine Group Differences at Day 1 and 21 Days After Last Vaccination With aTIV or TIV in Naive and Non-naive Subjects.</measure>
    <time_frame>Day 1 and Day 22 (vaccine non-naive subjects) or Day 50 (vaccine naive subjects) post vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentages of subjects with seroconversion in all three homologous virus strains, 21 days after last immunization, in subjects 6 to &lt;72 months of age, defined as: HI ≥ 40 subject with a pre-vaccination HI titer &lt;10; a minimum 4-fold increase HI titer for subjects with a prevaccination HI titer ≥10, on Day 22 (non-naive subjects) or Day 50 (naive subjects), as applicable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratios (GMRs) of HI and Vaccine Group Differences at Day 1 and 21 Days After Last Vaccination With aTIV or TIV in Naive and Non-naive Subjects.</measure>
    <time_frame>Day 1 and Day 22 (vaccine non-naive subjects) or Day 50 (vaccine naive subjects) post vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>GMRs of HI, day 22/day 1 (non-naive subjects) or day 50/day 1 (naive subjects) in all three homologous virus strains, 21 days after last immunization, in subjects 6 to &lt;72 months of age. As the non-inferiority of aTIV to TIV has been established, GMT ratio of aTIV relative to TIV in all three homologous virus strains, 21 days after last immunization in subjects 6 to &lt;72 months of age was evaluated using margins greater than the non-inferiority cut-off of 0.67.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With a HI Titer ≥ 40, ≥110 and ≥330 and Vaccine Group Differences at Day 1 and 21 Days After Last Vaccination With aTIV or TIV in Naive and Non-naive Subjects.</measure>
    <time_frame>Day 1 and Day 22 (vaccine non-naive subjects) or Day 50 (vaccine naive subjects) post vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of subjects with a HI titer ≥ 40, ≥110 and ≥330 on Day 1, Day 22 (non naïve subjects) or Day 50 (naïve subjects), in all three homologous virus strains, 21 days after last immunization, in subjects 6 to &lt;72 months of age.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">287</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>aTIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>aTIV is a trivalent influenza virus vaccine, adjuvanted with MF59C.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TIV is trivalent influenza vaccine licensed in Mexico.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29)</intervention_name>
    <description>A 0.25 mL (for children 6 to &lt;36 months old) and 0.5 mL (for children ≥36 months to &lt; 72 months old) dose of aTIV, a trivalent (surface antigen, formaldehyde-inactivated) influenza virus vaccine, adjuvanted with MF59C.1, administered at day 1 (for all subjects) and day 29 (for naïve subjects).</description>
    <arm_group_label>aTIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Non-adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29).</intervention_name>
    <description>A 0.25 mL (for children 6 to &lt;36 months old) and 0.5 mL (for children ≥36 months to &lt; 72 months old) dose of TIV , an egg-derived trivalent split influenza vaccine licensed in Mexico, administered at day 1 (for all subjects) and day 29 (for naïve subjects)</description>
    <arm_group_label>TIV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals of &gt;6 months through &lt;72 months of age on the day of informed consent.

          -  Individuals whose parent(s)/legal guardian(s) have voluntarily given written informed
             consent after the nature of the study has been explained according to local
             regulatory requirements, prior to study entry.

          -  Individuals who can comply with study procedures.

          -  Willingness to allow for serum samples to be stored beyond the study period, for
             potential additional future testing to better characterize immune response.

        Exclusion Criteria:

          -  Progressive, unstable or uncontrolled clinical conditions.

          -  Hypersensitivity, including allergy, to any component of vaccines, medicinal products
             or medical equipment whose use is foreseen in this study.

          -  History of progressive or severe neurologic disorder, seizure disorder or
             Guillian-Barré syndrome.

          -  Surgery planned during the study period that in the Investigator's opinion would
             interfere with the study visits schedule.

          -  Known bleeding diathesis, or any condition that may be associated with a prolonged
             bleeding time.

          -  Any fatal prognosis of an underlying medical condition (&lt;12 month life expectancy).

          -  Clinical conditions representing a contraindication to intramuscular vaccination and
             blood draws.

          -  Abnormal function of the immune system resulting from:

               1. Clinical conditions.

               2. Systemic administration of corticosteroids (PO/IV/IM) for more than 14
                  consecutive days within 90 days prior to informed consent.

               3. Administration of antineoplastic and immunomodulating agents or radiotherapy
                  within 90 days prior to informed consent.

          -  Received immunoglobulins or any blood products within 180 days prior to informed
             consent.

          -  Received an investigational or non-registered medicinal product within 30 days prior
             to informed consent.

          -  Study personnel as an immediate family or household member.

          -  Any other clinical condition that, in the opinion of the investigator, might
             interfere with the results of the study or pose additional risk to the subject due to
             participation in the study.

          -  Received any influenza vaccine (licensed or investigational) or with laboratory
             confirmed influenza within 6 months prior enrollment.

          -  Received any other vaccines within 14 days (for inactivated vaccines) or 28 days (for
             live vaccines) prior to enrolment in this study or who are planning to receive any
             vaccine within 28 days from the study vaccines.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>71 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>03, Centro Médico Universitario</name>
      <address>
        <city>Colonia Chamilpa, Cuernavaca</city>
        <state>Morelos</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>02, Unidad de Atencion Medica E Investigacion En Salud S.C (Unamis)</name>
      <address>
        <city>Mérida</city>
        <state>Yucatán</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>04, Medical Care and Research S.A. de C.V.</name>
      <address>
        <city>Mérida</city>
        <state>Yucatán</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 4, 2016</lastchanged_date>
  <firstreceived_date>September 30, 2014</firstreceived_date>
  <firstreceived_results_date>January 4, 2016</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled from 3 study centers in Mexico.</recruitment_details>
      <pre_assignment_details>All enrolled subjects were included in study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>aTIV (6 Months to &lt; 72 Months)</title>
          <description>A 0.25 mL (for children 6 to &lt;36 months old) and 0.5 mL (for children ≥36 months to &lt; 72 months old) dose of aTIV to be administered.</description>
        </group>
        <group group_id="P2">
          <title>TIV (6 Months to &lt; 72 Months)</title>
          <description>A 0.25 mL (for children 6 to &lt;36 months old) and 0.5 mL (for children ≥36 months to &lt; 72 months old) dose of TIV to be administered.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="143"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
                <participants group_id="P2" count="134"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>aTIV (6 Months to &lt; 72 Months)</title>
          <description>A 0.25 mL (for children 6 to &lt;36 months old) and 0.5 mL (for children ≥36 months to &lt; 72 months old) dose of aTIV to be administered.</description>
        </group>
        <group group_id="B2">
          <title>TIV (6 Months to &lt; 72 Months)</title>
          <description>A 0.25 mL (for children 6 to &lt;36 months old) and 0.5 mL (for children ≥36 months to &lt; 72 months old) dose of TIV to be administered.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="144"/>
                <measurement group_id="B2" value="143"/>
                <measurement group_id="B3" value="287"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="29.5" spread="18.2"/>
                <measurement group_id="B2" value="30.1" spread="19.1"/>
                <measurement group_id="B3" value="29.8" spread="18.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="68"/>
                <measurement group_id="B2" value="72"/>
                <measurement group_id="B3" value="140"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="76"/>
                <measurement group_id="B2" value="71"/>
                <measurement group_id="B3" value="147"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Naive Subjects 6 to &lt; 36 Months Old Reporting Solicited Local and Systemic Adverse Events (AEs) From Day 1 to Day 7 Following Each Vaccination.</title>
        <description>Number of naive subjects 6 to &lt; 36 months old reporting solicited local and systemic AEs from Day 1 to Day 7 after first vaccination and from Day 29 to Day 35 after second vaccination.</description>
        <time_frame>From Day 1 to Day 7 by vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis performed on the Solicited Safety Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Naive_aTIV (6 to &lt;36 Months)</title>
            <description>A 0.25 mL (for children 6 to &lt;36 months old) dose of aTIV to be administered.</description>
          </group>
          <group group_id="O2">
            <title>Naive_TIV (6 to &lt;36 Months)</title>
            <description>A 0.25 mL (for children 6 to &lt;36 months old) dose of TIV to be administered.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="68"/>
                  <measurement group_id="O2" value="69"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Naive Subjects 6 to &lt; 36 Months Old Reporting Solicited Local and Systemic Adverse Events (AEs) From Day 1 to Day 7 Following Each Vaccination.</title>
            <description>Number of naive subjects 6 to &lt; 36 months old reporting solicited local and systemic AEs from Day 1 to Day 7 after first vaccination and from Day 29 to Day 35 after second vaccination.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Local (Vac-1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Local (Vac-2, N= 67,67)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site ecchymosis (Vac-1, N= 65,69)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site ecchymosis (Vac-2, N= 66,67)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site induration (Vac-1, N= 66,69)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site induration (Vac-2, N= 66,67)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site swelling (Vac-1, N= 65,69)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site swelling (Vac-2, N= 66,67)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site erythema (Vac-1, N= 64,69)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site erythema (Vac-2, N= 66,67)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site tenderness (Vac-1, N= 66,69)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site tenderness (Vac-1, N= 66,66)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Systemic (Vac-1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Systemic (Vac-2, N=67,67)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Body Temperature (&gt;=40°C) (Vac-1, N= 67,68)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Body Temperature (&gt;=40°C) (Vac-2, N= 67,67)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever (Vac-1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever (Vac-2, N= 67,67)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change in eating habits (Vac-1, N= 67,69)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change in eating habits (Vac-2, N= 66,67)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarrhea (Vac-1, N= 67,69)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarrhea (Vac-2, N= 66,67)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Irritability (Vac-1, N= 67,69)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Irritability (Vac-2, N= 66,67)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Persistent Crying (Vac-1, N= 67,69)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Persistent Crying (Vac-2, N= 66,67)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sleepiness (Vac-1, N= 67,68)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sleepiness (Vac-2, N= 65,67)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vomiting (Vac-1, N= 67,68)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vomiting (Vac-2, N= 65,67)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Prevention of Pain and or Fever (Vac-1, N= 67,67)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Prevention of Pain and or Fever (Vac-2, N= 64,67)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Treatment of Pain and or Fever (Vac-1, N= 67,67)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Treatment of Pain and or Fever (Vac-1, N= 66,67)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Non-naive Subjects 6 to &lt; 36 Months Old Reporting Solicited Local and Systemic AEs From Day 1 to Day 7 After Vaccination.</title>
        <description>Number of non-naive subjects 6 to &lt; 36 months old reporting solicited local and systemic AEs from Day 1 to Day 7 after vaccination.</description>
        <time_frame>From Day 1 to Day 7</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis performed on the Solicited Safety Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-naive_aTIV (6 to &lt;36 Months)</title>
            <description>A 0.25 mL (for children 6 to &lt;36 months old) dose of aTIV to be administered.</description>
          </group>
          <group group_id="O2">
            <title>Non-naive_TIV (6 to &lt;36 Months)</title>
            <description>A 0.25 mL (for children 6 to &lt;36 months old) dose of TIV to be administered.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Non-naive Subjects 6 to &lt; 36 Months Old Reporting Solicited Local and Systemic AEs From Day 1 to Day 7 After Vaccination.</title>
            <description>Number of non-naive subjects 6 to &lt; 36 months old reporting solicited local and systemic AEs from Day 1 to Day 7 after vaccination.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Local</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site ecchymosis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site induration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site erythema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site tenderness (N= 22,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Systemic</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Body Temperature (&gt;= 40.0°C)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change in eating habits</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarrhea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Irritability</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Persistent Crying</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sleepiness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vomiting (N= 21,21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Prevention of Pain and or Fever (N= 21,22)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Treatment of Pain and or Fever (N= 21,22)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Naive Subjects ≥ 36 Months to &lt; 72 Months Old Reporting Solicited Local and Systemic AEs From Day 1 to Day 7 Following Each Vaccination.</title>
        <description>Number of naive subjects ≥ 36 months to &lt; 72 months old reporting solicited local and systemic AEs from Day 1 to Day 7 after first vaccination and from Day 29 to Day 35 after second vaccination.</description>
        <time_frame>From Day 1 to Day 7 by vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis performed on the Solicited Safety Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Naive_aTIV (≥36 Months to &lt; 72 Months)</title>
            <description>A 0.5 mL (for children ≥36 months to &lt; 72 months old) dose of aTIV to be administered.</description>
          </group>
          <group group_id="O2">
            <title>Naive_TIV (≥36 Months to &lt; 72 Months)</title>
            <description>A 0.5 mL (for children ≥36 months to &lt; 72 months old) dose of TIV to be administered.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Naive Subjects ≥ 36 Months to &lt; 72 Months Old Reporting Solicited Local and Systemic AEs From Day 1 to Day 7 Following Each Vaccination.</title>
            <description>Number of naive subjects ≥ 36 months to &lt; 72 months old reporting solicited local and systemic AEs from Day 1 to Day 7 after first vaccination and from Day 29 to Day 35 after second vaccination.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Local (Vac-1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Local (Vac-2, N= 6,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site ecchymosis (Vac-1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site ecchymosis (Vac-2, N= 6,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site induration (Vac-1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site induration (Vac-2, N= 6,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site swelling (Vac-1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site swelling (Vac-2, N= 6,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site erythema (Vac-1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site erythema (Vac-2, N= 6,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site pain (Vac-1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site pain (Vac-2, N= 6,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Systemic (Vac-1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Systemic (Vac-2, N= 6,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue (Vac-1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue (Vac-2, N= 6,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Myalgia (Vac-1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Myalgia (Vac-2, N= 6,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Arthralgia (Vac-1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Arthralgia (Vac-2, N= 6,2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache (Vac-1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache (Vac-2, N= 6,2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Body Temperature (&gt;= 40.0°C) (Vac-1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Body Temperature (&gt;= 40.0°C) (Vac-2, N= 6,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever (Vac-1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever (Vac-2, N= 6,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chills (Vac-1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chills (Vac-2, N= 6,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change in Eating Habits (Vac-1, N= 5,4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change in Eating Habits (Vac-2, N= 6,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarrhea (Vac-1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarrhea (Vac-2, N= 6,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vomiting (Vac-1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vomiting (Vac-2, N= 6,3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Prevention of Pain and or Fever (Vac-1, N= 6,2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Prevention of Pain and or Fever (Vac-2, N= 4,2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Treatment of Pain and or Fever (Vac-1, N= 6,2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Treatment of Pain and or Fever (Vac-2, N= 5,2)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Non-naive Subjects ≥36 Months to &lt; 72 Months Old Reporting Solicited Local and Systemic AEs From Day 1 to Day 7 Following Each Vaccination.</title>
        <description>Number of non-naive subjects ≥36 months to &lt; 72 months old reporting solicited local and systemic AEs from Day 1 to Day 7 after vaccination.</description>
        <time_frame>From Day 1 to Day 7</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis performed on the Solicited Safety Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-naive_aTIV (≥36 Months to &lt; 72 Months)</title>
            <description>A 0.5 mL (for children ≥36 months to &lt; 72 months old) dose of aTIV to be administered.</description>
          </group>
          <group group_id="O2">
            <title>Non-naive_TIV (≥36 Months to &lt; 72 Months)</title>
            <description>A 0.5 mL (for children ≥36 months to &lt; 72 months old) dose of TIV to be administered.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="44"/>
                  <measurement group_id="O2" value="41"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Non-naive Subjects ≥36 Months to &lt; 72 Months Old Reporting Solicited Local and Systemic AEs From Day 1 to Day 7 Following Each Vaccination.</title>
            <description>Number of non-naive subjects ≥36 months to &lt; 72 months old reporting solicited local and systemic AEs from Day 1 to Day 7 after vaccination.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Local</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site ecchymosis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site induration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site erythema (N= 43,40)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site pain (N= 44,40)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site tenderness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Systemic</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue (N= 44,40)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Myalgia (N= 44,40)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Arthralgia (N= 44,40)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache (N= 44,40)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Body Temperature (&gt;= 40.0°C) (N= 44,40)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chills (N= 44,40)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change in eating habits (N= 44,39)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarrhea (N= 44,39)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vomiting (N= 44,40)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Prevention of Pain and or Fever (N= 42,40)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Treatment of Pain and or Fever (N=42,40)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Naive Subjects Aged 6 to &lt; 72 Months Reporting All Unsolicited AEs From Day 1 to Day 50.</title>
        <description>Number of naive subjects aged 6 to &lt; 72 months reporting all unsolicited AEs, medically attended AEs, AE leading to study withdrawal and serious AEs (SAEs) from Day 1 to Day 50.</description>
        <time_frame>From Day 1 to Day 50</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis performed on the Unsolicited Safety Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Naive_aTIV (6 Months to &lt; 72 Months)</title>
            <description>A 0.25 mL (for children 6 to &lt;36 months old) and 0.5 mL (for children ≥36 months to &lt; 72 months old) dose of aTIV to be administered.</description>
          </group>
          <group group_id="O2">
            <title>Naive_TIV (6 Months to &lt; 72 Months)</title>
            <description>A 0.25 mL (for children 6 to &lt;36 months old) and 0.5 mL (for children ≥36 months to &lt; 72 months old) dose of TIV to be administered.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="74"/>
                  <measurement group_id="O2" value="73"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Naive Subjects Aged 6 to &lt; 72 Months Reporting All Unsolicited AEs From Day 1 to Day 50.</title>
            <description>Number of naive subjects aged 6 to &lt; 72 months reporting all unsolicited AEs, medically attended AEs, AE leading to study withdrawal and serious AEs (SAEs) from Day 1 to Day 50.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any AE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>At least Possibly related AE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>SAE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>At least possibly related SAE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AE leading to study withdrawal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Medically attended AE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Death</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Non-naive Subjects Aged 6 to &lt; 72 Months Reporting All Unsolicited AEs From Day 1 to Day 22</title>
        <description>Number of non-naive subjects aged 6 to &lt; 72 months reporting all unsolicited AEs, medically attended AEs, AE leading to study withdrawal and SAEs from Day 1 to Day 22.</description>
        <time_frame>From Day 1 to Day 22</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis performed on the Unsolicited Safety Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Non naive_aTIV (6 Months to &lt; 72 Months)</title>
            <description>A 0.25 mL (for children 6 to &lt;36 months old) and 0.5 mL (for children ≥36 months to &lt; 72 months old) dose of aTIV to be administered.</description>
          </group>
          <group group_id="O2">
            <title>Non naive_TIV (6 Months to &lt; 72 Months)</title>
            <description>A 0.25 mL (for children 6 to &lt;36 months old) and 0.5 mL (for children ≥36 months to &lt; 72 months old) dose of TIV to be administered.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="66"/>
                  <measurement group_id="O2" value="64"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Non-naive Subjects Aged 6 to &lt; 72 Months Reporting All Unsolicited AEs From Day 1 to Day 22</title>
            <description>Number of non-naive subjects aged 6 to &lt; 72 months reporting all unsolicited AEs, medically attended AEs, AE leading to study withdrawal and SAEs from Day 1 to Day 22.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any AE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>At least Possibly related AE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>SAE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>At least possibly related SAE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AE leading to study withdrawal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Medically attended AE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Death</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs), in All Three Homologous Virus Strains in Subjects 6 to &lt; 72 Months of Age.</title>
        <description>Antibody response was assessed in terms of GMTs in all three homologous virus strains, 21 days after last immunization, in subjects 6 to &lt;72 months of age.
The study is considered a success if the 21 days after last immunization GMT ratios of aTIV relative to TIV demonstrate as non-inferior with the lower limit (LL) of the two sided 95% confidence interval (CI) above 0.67 (-0.176 on log10 scale) for each vaccine strain (Center for Biologics Evaluation and Research {CBER} Guideline on Seasonal Vaccines May 2007).</description>
        <time_frame>Day 1 and Day 22 (vaccine non-naïve subjects) or Day 50 (vaccine naïve subjects) post vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis performed on the Per Protocol Set.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (6 Months to &lt; 72 Months)</title>
            <description>A 0.25 mL (for children 6 to &lt;36 months old) and 0.5 mL (for children ≥36 months to &lt; 72 months old) dose of aTIV to be administered.</description>
          </group>
          <group group_id="O2">
            <title>TIV (6 Months to &lt; 72 Months)</title>
            <description>A 0.25 mL (for children 6 to &lt;36 months old) and 0.5 mL (for children ≥36 months to &lt; 72 months old) dose of TIV to be administered.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="114"/>
                  <measurement group_id="O2" value="112"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Titers (GMTs), in All Three Homologous Virus Strains in Subjects 6 to &lt; 72 Months of Age.</title>
            <description>Antibody response was assessed in terms of GMTs in all three homologous virus strains, 21 days after last immunization, in subjects 6 to &lt;72 months of age.
The study is considered a success if the 21 days after last immunization GMT ratios of aTIV relative to TIV demonstrate as non-inferior with the lower limit (LL) of the two sided 95% confidence interval (CI) above 0.67 (-0.176 on log10 scale) for each vaccine strain (Center for Biologics Evaluation and Research {CBER} Guideline on Seasonal Vaccines May 2007).</description>
            <units>Titers</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>A/H1N1 (Day 1) (N= 113,112)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14" lower_limit="11" upper_limit="19"/>
                  <measurement group_id="O2" value="15" lower_limit="11" upper_limit="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/H1N1 (Day 22 or Day 50)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="675" lower_limit="536" upper_limit="849"/>
                  <measurement group_id="O2" value="166" lower_limit="132" upper_limit="208"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/H3N2 (Day 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="59" lower_limit="40" upper_limit="86"/>
                  <measurement group_id="O2" value="55" lower_limit="38" upper_limit="81"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/H3N2 (Day 22 or Day 50)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1280" lower_limit="1077" upper_limit="1521"/>
                  <measurement group_id="O2" value="495" lower_limit="417" upper_limit="588"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B (Day 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.47" lower_limit="6.41" upper_limit="8.71"/>
                  <measurement group_id="O2" value="6.92" lower_limit="5.95" upper_limit="8.06"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B (Day 22 or Day 50)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="76" lower_limit="61" upper_limit="93"/>
                  <measurement group_id="O2" value="16" lower_limit="13" upper_limit="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric mean titers (GMTs), in H1N1 strain of all the tree strains in Subjects 6 to &lt; 72 months of Age.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Hypothesis: Demonstrate non-inferiority (NI) of aTIV to TIV:
H0 : μAi - μBi ≤ -0.176 (Null) H1 : μAi – μBi &gt;-0.176 (alternative) (i= H1N1, H3N2, B) μA and μB are means of log10-transformed titers 21 days after last vaccination of the aTIV &amp; TIV vaccine groups respectively. NI is claimed if LL of 95% CI for GMT ratios is &gt;0.67.
Significance level is α = 2.5% (1-sided), which needs no further adjustment for multiplicity as to reach NI, above hypothesis needs to be rejected for all 3 strains.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>4.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.00</ci_lower_limit>
            <ci_upper_limit>5.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric mean titers (GMTs), in H3N2 strain of all three homologous virus strains in Subjects 6 to &lt; 72 months of Age.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Hypothesis: Demonstrate non-inferiority (NI) of aTIV to TIV:
H0 : μAi - μBi ≤ -0.176 (Null) H1 : μAi - μBi &gt;-0.176 (alternative) (i= H1N1, H3N2, B) μA and μB are means of log10-transformed titers 21 days after last vaccination of the aTIV &amp; TIV vaccine groups respectively. NI is claimed if LL of 95% CI for GMT ratios is &gt;0.67.
Significance level is α = 2.5% (1-sided), which needs no further adjustment for multiplicity as to reach NI, above hypothesis needs to be rejected for all 3 strains.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>2.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.05</ci_lower_limit>
            <ci_upper_limit>3.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric mean titers (GMTs), in B strain of all three homologous virus strains in Subjects 6 to &lt; 72 months of Age.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Hypothesis: Demonstrate non-inferiority (NI) of aTIV to TIV:
H0 : μAi - μBi ≤ -0.176 (Null) H1 : μAi - μBi &gt;-0.176 (alternative) (i= H1N1, H3N2, B) μA and μB are means of log10-transformed titers 21 days after last vaccination of the aTIV &amp; TIV vaccine groups respectively. NI is claimed if LL of 95% CI for GMT ratios is &gt;0.67.
Significance level is α = 2.5% (1-sided), which needs no further adjustment for multiplicity as to reach NI, above hypothesis needs to be rejected for all 3 strains.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>4.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.52</ci_lower_limit>
            <ci_upper_limit>6.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects Achieving Seroconversion in Hemagglutination Inhibition (HI) Titers and Vaccine Group Differences at Day 1 and 21 Days After Last Vaccination With aTIV or TIV in Naive and Non-naive Subjects.</title>
        <description>Percentages of subjects with seroconversion in all three homologous virus strains, 21 days after last immunization, in subjects 6 to &lt;72 months of age, defined as: HI ≥ 40 subject with a pre-vaccination HI titer &lt;10; a minimum 4-fold increase HI titer for subjects with a prevaccination HI titer ≥10, on Day 22 (non-naive subjects) or Day 50 (naive subjects), as applicable.</description>
        <time_frame>Day 1 and Day 22 (vaccine non-naive subjects) or Day 50 (vaccine naive subjects) post vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis performed on the Per Protocol Set.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (6 Months to &lt; 72 Months)</title>
            <description>A 0.25 mL (for children 6 to &lt;36 months old) and 0.5 mL (for children ≥36 months to &lt; 72 months old) dose of aTIV to be administered.</description>
          </group>
          <group group_id="O2">
            <title>TIV (6 Months to &lt; 72 Months)</title>
            <description>A 0.25 mL (for children 6 to &lt;36 months old) and 0.5 mL (for children ≥36 months to &lt; 72 months old) dose of TIV to be administered.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="114"/>
                  <measurement group_id="O2" value="112"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentages of Subjects Achieving Seroconversion in Hemagglutination Inhibition (HI) Titers and Vaccine Group Differences at Day 1 and 21 Days After Last Vaccination With aTIV or TIV in Naive and Non-naive Subjects.</title>
            <description>Percentages of subjects with seroconversion in all three homologous virus strains, 21 days after last immunization, in subjects 6 to &lt;72 months of age, defined as: HI ≥ 40 subject with a pre-vaccination HI titer &lt;10; a minimum 4-fold increase HI titer for subjects with a prevaccination HI titer ≥10, on Day 22 (non-naive subjects) or Day 50 (naive subjects), as applicable.</description>
            <units>Percentages of subjects</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>H1N1 strain (N= 113,112)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="90" lower_limit="83.2" upper_limit="95"/>
                  <measurement group_id="O2" value="75" lower_limit="65.9" upper_limit="82.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>H3N2 strain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="77" lower_limit="68.4" upper_limit="84.5"/>
                  <measurement group_id="O2" value="67" lower_limit="57.4" upper_limit="75.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B strain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="78" lower_limit="69.4" upper_limit="85.3"/>
                  <measurement group_id="O2" value="22" lower_limit="15" upper_limit="31.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percentage of subjects achieving seroconversion in H1N1 strain after last vaccination with aTIV or TIV in naïve and non-naive subjects.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The following hypotheses should be tested to demonstrate non-inferiority of aTIV to TIV:
H0i: πi1 &gt; πi2-0.1 vs. H1i: πi1 &gt; πi2- 0.1 where H0i and H1i represent the null and the alternative hypothesis (respectively) of the non- inferiority objective and πi1 and πi2 represent the seroresponse rates 21 days after last immunization of the aTIV and TIV vaccine groups respectively in the i-th strain (H1N1, H3N2, B). The non-inferiority criterion is -0.1 (i.e., -10%).</non_inferiority_desc>
            <param_type>Vaccine Group Differences</param_type>
            <param_value>17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.1</ci_lower_limit>
            <ci_upper_limit>26.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percentage of subjects achieving seroconversion in H3N2 strain after last vaccination with aTIV or TIV in naive and non-naive subjects.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The following hypotheses should be tested to demonstrate non-inferiority of aTIV to TIV:
H0i: πi1 &gt; πi2-0.1 vs. H1i: πi1 &gt; πi2- 0.1 where H0i and H1i represent the null and the alternative hypothesis (respectively) of the non- inferiority objective and πi1 and πi2 represent the seroresponse rates 21 days after last immunization of the aTIV and TIV vaccine groups respectively in the i-th strain (H1N1, H3N2, B). The non-inferiority criterion is -0.1 (i.e., -10%).</non_inferiority_desc>
            <param_type>Vaccine Group Differences</param_type>
            <param_value>10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percentage of subjects achieving seroconversion in B strains after last vaccination with aTIV or TIV in naïve and non naive subjects.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The following hypotheses should be tested to demonstrate non-inferiority of aTIV to TIV:
H0i: πi1 &gt; πi2-0.1 vs. H1i: πi1 &gt; πi2- 0.1 where H0i and H1i represent the null and the alternative hypothesis (respectively) of the non- inferiority objective and πi1 and πi2 represent the seroresponse rates 21 days after last immunization of the aTIV and TIV vaccine groups respectively in the i-th strain (H1N1, H3N2, B). The non-inferiority criterion is -0.1 (i.e., -10%).</non_inferiority_desc>
            <param_type>Vaccine Group Differences</param_type>
            <param_value>58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>47.5</ci_lower_limit>
            <ci_upper_limit>68.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratios (GMRs) of HI and Vaccine Group Differences at Day 1 and 21 Days After Last Vaccination With aTIV or TIV in Naive and Non-naive Subjects.</title>
        <description>GMRs of HI, day 22/day 1 (non-naive subjects) or day 50/day 1 (naive subjects) in all three homologous virus strains, 21 days after last immunization, in subjects 6 to &lt;72 months of age. As the non-inferiority of aTIV to TIV has been established, GMT ratio of aTIV relative to TIV in all three homologous virus strains, 21 days after last immunization in subjects 6 to &lt;72 months of age was evaluated using margins greater than the non-inferiority cut-off of 0.67.</description>
        <time_frame>Day 1 and Day 22 (vaccine non-naive subjects) or Day 50 (vaccine naive subjects) post vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis performed on the Per Protocol Set.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (6 Months to &lt; 72 Months)</title>
            <description>A 0.25 mL (for children 6 to &lt;36 months old) and 0.5 mL (for children ≥36 months to &lt; 72 months old) dose of aTIV to be administered.</description>
          </group>
          <group group_id="O2">
            <title>TIV (6 Months to &lt; 72 Months)</title>
            <description>A 0.25 mL (for children 6 to &lt;36 months old) and 0.5 mL (for children ≥36 months to &lt; 72 months old) dose of TIV to be administered.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="114"/>
                  <measurement group_id="O2" value="112"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Ratios (GMRs) of HI and Vaccine Group Differences at Day 1 and 21 Days After Last Vaccination With aTIV or TIV in Naive and Non-naive Subjects.</title>
            <description>GMRs of HI, day 22/day 1 (non-naive subjects) or day 50/day 1 (naive subjects) in all three homologous virus strains, 21 days after last immunization, in subjects 6 to &lt;72 months of age. As the non-inferiority of aTIV to TIV has been established, GMT ratio of aTIV relative to TIV in all three homologous virus strains, 21 days after last immunization in subjects 6 to &lt;72 months of age was evaluated using margins greater than the non-inferiority cut-off of 0.67.</description>
            <units>Ratios</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>H1N1 strain (N=113,112)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="46" lower_limit="34" upper_limit="62"/>
                  <measurement group_id="O2" value="11" lower_limit="8.12" upper_limit="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>H3N2 strain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21" lower_limit="16" upper_limit="28"/>
                  <measurement group_id="O2" value="8.39" lower_limit="6.26" upper_limit="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B strain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10" lower_limit="8.25" upper_limit="13"/>
                  <measurement group_id="O2" value="2.30" lower_limit="1.84" upper_limit="2.87"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With a HI Titer ≥ 40, ≥110 and ≥330 and Vaccine Group Differences at Day 1 and 21 Days After Last Vaccination With aTIV or TIV in Naive and Non-naive Subjects.</title>
        <description>Percentage of subjects with a HI titer ≥ 40, ≥110 and ≥330 on Day 1, Day 22 (non naïve subjects) or Day 50 (naïve subjects), in all three homologous virus strains, 21 days after last immunization, in subjects 6 to &lt;72 months of age.</description>
        <time_frame>Day 1 and Day 22 (vaccine non-naive subjects) or Day 50 (vaccine naive subjects) post vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis performed on the Per Protocol Set.</population>
        <group_list>
          <group group_id="O1">
            <title>aTIV (6 Months to &lt; 72 Months)</title>
            <description>A 0.25 mL (for children 6 to &lt;36 months old) and 0.5 mL (for children ≥36 months to &lt; 72 months old) dose of aTIV to be administered.</description>
          </group>
          <group group_id="O2">
            <title>TIV (6 Months to &lt; 72 Months)</title>
            <description>A 0.25 mL (for children 6 to &lt;36 months old) and 0.5 mL (for children ≥36 months to &lt; 72 months old) dose of TIV to be administered.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="114"/>
                  <measurement group_id="O2" value="112"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentages of Subjects With a HI Titer ≥ 40, ≥110 and ≥330 and Vaccine Group Differences at Day 1 and 21 Days After Last Vaccination With aTIV or TIV in Naive and Non-naive Subjects.</title>
            <description>Percentage of subjects with a HI titer ≥ 40, ≥110 and ≥330 on Day 1, Day 22 (non naïve subjects) or Day 50 (naïve subjects), in all three homologous virus strains, 21 days after last immunization, in subjects 6 to &lt;72 months of age.</description>
            <units>Percentage of subjects</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>H1N1 strain (HI titer ≥ 40, Day 1) (N=113,112)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32" lower_limit="23.4" upper_limit="41.3"/>
                  <measurement group_id="O2" value="33" lower_limit="24.4" upper_limit="42.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>H1N1 strain (HI titer ≥ 40, Day 22 or Day 50)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="99" lower_limit="95.2" upper_limit="99.98"/>
                  <measurement group_id="O2" value="88" lower_limit="81" upper_limit="93.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>H1N1 strain (HI titer ≥ 110, Day 1) (N=113,112)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19" lower_limit="11.9" upper_limit="27"/>
                  <measurement group_id="O2" value="20" lower_limit="12.7" upper_limit="28.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>H1N1 strain (HI titer ≥ 110, Day 22 or Day 50)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="96" lower_limit="90.1" upper_limit="98.6"/>
                  <measurement group_id="O2" value="68" lower_limit="58.4" upper_limit="76.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>H1N1 strain (HI titer ≥ 330, Day 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4" lower_limit="1.5" upper_limit="10"/>
                  <measurement group_id="O2" value="7" lower_limit="3.1" upper_limit="13.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>H1N1 strain (HI titer ≥ 330, Day 22 or Day 50)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="78" lower_limit="69.4" upper_limit="85.3"/>
                  <measurement group_id="O2" value="37" lower_limit="27.7" upper_limit="46.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>H3N2 strain (HI titer ≥ 40, Day 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56" lower_limit="46.5" upper_limit="65.4"/>
                  <measurement group_id="O2" value="58" lower_limit="48.3" upper_limit="67.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>H3N2 strain (HI titer ≥ 40, Day 22 or Day 50)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100" lower_limit="96.8" upper_limit="100"/>
                  <measurement group_id="O2" value="97" lower_limit="92.4" upper_limit="99.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>H3N2 strain (HI titer ≥ 110, Day 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="44" lower_limit="34.6" upper_limit="53.5"/>
                  <measurement group_id="O2" value="44" lower_limit="34.4" upper_limit="53.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>H3N2 strain (HI titer ≥ 110, Day 22 or Day 50)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="99" lower_limit="95.2" upper_limit="99.98"/>
                  <measurement group_id="O2" value="84" lower_limit="75.8" upper_limit="90.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>H3N2 strain (HI titer ≥ 330, Day 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33" lower_limit="24.8" upper_limit="42.8"/>
                  <measurement group_id="O2" value="30" lower_limit="22" upper_limit="39.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>H3N2 strain (HI titer ≥ 330, Day 22 or Day 50)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="86" lower_limit="78.2" upper_limit="91.8"/>
                  <measurement group_id="O2" value="61" lower_limit="51" upper_limit="69.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B strain (HI titer ≥ 40, Day 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9" lower_limit="4.3" upper_limit="15.5"/>
                  <measurement group_id="O2" value="9" lower_limit="4.4" upper_limit="15.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B strain (HI titer ≥ 40, Day 22 or Day 50)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="84" lower_limit="76.2" upper_limit="90.4"/>
                  <measurement group_id="O2" value="32" lower_limit="23.6" upper_limit="41.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B strain (HI titer ≥ 110, Day 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2" lower_limit="0.21" upper_limit="6.2"/>
                  <measurement group_id="O2" value="1" lower_limit="0.02" upper_limit="4.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B strain (HI titer ≥ 110, Day 22 or Day 50)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43" lower_limit="33.7" upper_limit="52.6"/>
                  <measurement group_id="O2" value="6" lower_limit="2.5" upper_limit="12.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B strain (HI titer ≥ 330, Day 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0" lower_limit="0" upper_limit="3.2"/>
                  <measurement group_id="O2" value="0" lower_limit="0" upper_limit="3.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B strain (HI titer ≥ 330, Day 22 or Day 50)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8" lower_limit="3.7" upper_limit="14.5"/>
                  <measurement group_id="O2" value="0" lower_limit="0" upper_limit="3.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the study; Day 1 - Day 50 (naive subjects) and Day 1 - Day 22 (non-naive subjects).</time_frame>
      <desc>Solicited AEs were collected by the subject parent(s)/legal guardian(s) for 7 days from the day of vaccination/s (Day 1 &amp; Day 29 for naive; Day 1 for non-naive). Unsolicited AEs were collected from Day 1 to Day 50 for naive, from Day 1 to Day 22 for non-naive.
All AEs were monitored until resolution or the investigator assesses them as stable.</desc>
      <group_list>
        <group group_id="E1">
          <title>Naive_aTIV (6 Months to &lt; 72 Months)</title>
          <description>A 0.25 mL (for children 6 to &lt;36 months old) and 0.5 mL (for children ≥36 months to &lt; 72 months old) dose of aTIV to be administered (Naive).</description>
        </group>
        <group group_id="E2">
          <title>Naive_TIV (6 Months to &lt; 72 Months)</title>
          <description>A 0.25 mL (for children 6 to &lt;36 months old) and 0.5 mL (for children ≥36 months to &lt; 72 months old) dose of TIV to be administered (Naive).</description>
        </group>
        <group group_id="E3">
          <title>Non-naive_aTIV (6 Months to &lt; 72 Months)</title>
          <description>A 0.25 mL (for children 6 to &lt;36 months old) and 0.5 mL (for children ≥36 months to &lt; 72 months old) dose of aTIV to be administered (Non-naive).</description>
        </group>
        <group group_id="E4">
          <title>Non-naive_TIV (6 Months to &lt; 72 Months)</title>
          <description>A 0.25 mL (for children 6 to &lt;36 months old) and 0.5 mL (for children ≥36 months to &lt; 72 months old) dose of TIV to be administered (Non-naive).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Eating disorder</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis’ agreement with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publications of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
